872728-85-3

Basic information

• Product Name: N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate
• Synonyms: N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate;InterMediates of Dabigatran;N-[[2-[[[4-(AMinoiMinoMethyl)phenyl]aMino]Methyl]-1- Methyl-1H-benziMidazol-5-yl] carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-Methylbenzenesulfonate;N-[[2-[[[4-(AMinoiMinoMethyl)phenyl]aMino]Methyl]-1- Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester tosylate;β-Alanine, N-[[2-[[[4-(aMinoiMinoMethyl)phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester, 4-Methylbenzenesulfonat;-Alanine,N- 2- 4-(aMinoiMinoMethyl)phenyl aMino Methyl -1-Methyl-1H-benziMidazol-5-yl carbonyl -N-2-pyridinyl-,ethyl ester,4-Methylbenzenesulfonate(1 1);Ethyl 3-(2-(((4-carbaMiMidoylphenyl)aMino)Methyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate 4-Methylbenzenesulfonate;Dabigatran ethyl ester tosylate
• CAS NO: 872728-85-3
• Molecular Formula: C₇H₈O₃S*C₂₇H₂₉N₇O₃
• Molecular Weight: 777.88628
• EINECS: 1308068-626-2
• Product Categories: Intermediate of Dabigatran
• Mol File: 872728-85-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate(872728-85-3)
• EPA Substance Registry System: N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate(872728-85-3)

Safety Data

• Hazardous Substances Data: 872728-85-3(Hazardous Substances Data)

Usage

General Description

N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]arbonyl]-N-2-pyridinyl-beta-alanine ethyl ester 4-methylbenzenesulfonate is a complex chemical compound that consists of a benzimidazol-5-yl group, an ethyl ester group, a beta-alanine group, and a 4-methylbenzenesulfonate group. The compound also contains an aminoiminomethylphenyl group and a pyridinyl group. This chemical may have applications in pharmaceuticals, research, and other industries due to its unique molecular structure and potentially valuable properties. Further research and analysis are likely needed to fully understand the potential uses and effects of this compound.

Upstream product

• 429658-95-7 3-({2-[(4-carbamimidoylphenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester 
• 66630-74-8 4-amino-3-(methylamino)benzoic acid 
• 211915-84-3 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl ester 
• 104-15-4 toluene-4-sulfonic acid 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 
• 42288-26-6 (4-cyanophenyl)glycine 
• 67-56-1 methanol 
• 872728-84-2 1-methyl-2-[N-[4-(1,2,4-oxadiazol-5-one-3-yl)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide 

Downstream Products

• 872728-81-9 dabigatran etexilate mesylate 
• 211915-06-9 dabigatran etexilate 
• 872728-81-9 N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl] amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-β-alanine ethyl ester methanesulfonate 
• 211915-06-9 dabigatran etexilate 
• 211915-06-9 ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate 
• 211915-06-9 dabigatran etexilate 
• 1381757-44-3 2-(N-(3-ethoxy-3-oxopropyl)-2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)pyridine-1-oxide 

Relevant articles and documents

Improved method for preparing dabigatran etexilate intermediate

The invention belongs to the field of medical intermediate synthetic methods, and relates to an improved method for preparing a dabigatran etexilate intermediate, in particular, a synthetic method of3-[[[2-[[(4-amidinophenyl)amino]methyl]-1H-benzimidazole-5-yl]carbonyl](pyridine-2-yl)amino] ethyl propionate p-toluene sulfonate 1. According to the method, use of a large amount of solvents and hydrogen chloride is avoided, the reaction process is stable, the dosage of reactants is easy to control, on one hand, impurities generated by side reactions are reduced, and subsequent synthesized dabigatran etexilate is easier to purify; on the other hand, wastes caused by release of saturated hydrogen chloride gas are greatly reduced, the environmental pollution is reduced, meanwhile the steps aresimple and easy to control, and the method is suitable for large-scale production.

Preparation process of Pradaxa

The invention discloses a preparation process of Pradaxa. After obtaining a compound 3 with the structural formula as shown in the description, an alkali liquor is added to separate out the compound 3; micro-molecule alcohol is used for refining; under the action of a reaction solvent and an organic alkali, the compound 3 and hexyl chloroformate conduct a condensation reaction to obtain a compound2 with the structural formula as shown in the description; an acid liquor is used for washing, and vacuum concentration is performed till the product is dry; an organic solvent is used for refining;and the compound 2 and methanesulfonic acid are salified to obtain Pradaxa. Through the continuous operation that solid-liquid separation is performed after the alkali liquor is added to separate outthe compound 3, the problems that lots of acid is evaporated to corrode equipment due to vacuum concentration and many degradation impurities are produced by heating are solved. The pickling process is adopted to control specific impurities in a reaction liquid of the compound 2. At last, an appropriate methanesulfonic acid charge ratio and an appropriate charging temperature are adopted to guarantee correct product crystal forms.

Identification, synthesis, and strategy for the reduction of potential impurities observed in dabigatran etexilate mesylate processes

Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and 1H and 13C NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.